

CLAIMS

What is claimed is:

1. A method of identifying a candidate psychiatric patient for treatment with medication that acts at a D2 dopamine receptor or influences D2 dopamine receptor density,
5 the method comprising:

determining whether the patient's DRD2 genotype is Taq1A allele positive (A1+) or Taq1A allele negative (A1-);

wherein the patient's DRD2 genotype provides a basis for selecting treatment.
2. The method of claim 1, wherein:
10 an A1+ genotype is indicative of a candidate for treatment with high dose high DRD2 binding atypical antipsychotics and/or SSRIs that increase D2 dopamine receptor density; and

an A1- genotype is indicative of a candidate for treatment with low dose high or low D2 dopamine receptor binding atypical antipsychotics or alternative antidepressant.
- 15 2. The method of claim 1, wherein the psychiatric patient suffers from schizophrenia.
3. The method of claim 1, wherein the patient suffers from post-traumatic stress disorder (PTSD), depression, social anxiety or mixed anxiety and depressive states.
4. The method of claim 1 when the patient suffers from Parkinson's disease.